Evidence map›Paper›PMID 24990355›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2014

Gold nanoparticle hyperthermia reduces radiotherapy dose.

James F Hainfeld, Lynn Lin, Daniel N Slatkin, F Avraham Dilmanian, Timothy M Vadas, Henry M Smilowitz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Comprehensive comparison of theranostic nanoparticles in breast cancer.American journal of clinical and experimental immunology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

James F HainfeldNanoprobes, Inc., Yaphank, NY, USA. Electronic address: hainfeld@nanoprobes.com.
Lynn LinNanoprobes, Inc., USA.
Daniel N SlatkinNanoprobes, Inc., USA.
F Avraham DilmanianDepartment of Radiation Oncology, State University of New York at Stony Brook, USA.
Timothy M VadasDepartment of Civil and Environmental Engineering, University of Connecticut, USA.
Henry M SmilowitzDepartment of Cell Biology, University of Connecticut Health Center, USA.

Funding

Infrared & X-ray Nanogold Therapy of Head & Neck CancersR44CA130225 · NCI · NANOPROBES, INC. · PI HAINFELD, JAMES F · 2008 to 2012
$987k
NCI NIH HHS 1R44CA130225NCI NIH HHS R44 CA130225
6 · The paper itself

Abstract

Gold nanoparticles can absorb near infrared light, resulting in heating and ablation of tumors. Gold nanoparticles have also been used for enhancing the X-ray dose to tumors. The combination of hyperthermia and radiotherapy is synergistic, importantly allowing a reduction in X-ray dose with improved therapeutic results. Here we intratumorally infused small 15 nm gold nanoparticles engineered to be transformed from infrared-transparent to infrared-absorptive by the tumor, then heated by infrared followed by X-ray treatment. Synergy was studied using a very radioresistant subcutaneous squamous cell carcinoma (SCCVII) in mice. It was found that the dose required to control 50% of the tumors, normally 55 Gy, could be reduced to <15 Gy (a factor of >3.7). Gold nanoparticles therefore provide a method to combine hyperthermia and radiotherapy to drastically reduce the X-ray radiation needed, thus sparing normal tissue, reducing side effects, and making radiotherapy more effective. FROM THE CLINICAL EDITOR: Gold nanoparticles are known to enhance the efficacy of X-ray in tumor irradiation resulting in tumor heating and ablation. They also absorb near infrared light. This dual property was studied using a very radioresistant subcutaneous squamous cell carcinoma in mice, demonstrating that the dose required to control 50% of the tumors could be reduced by a factor of > 3.7, paving the way to potential future clinical applications.

Indexed as

AnimalsCarcinoma, Squamous CellGoldHumansHyperthermia, InducedMaleMetal NanoparticlesMiceMice, NudeRadiotherapyGoldCancerGold nanoparticlesHyperthermiaRadiotherapy

Identifiers

PMID24990355
PMCPMC4253648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.